V Eleftheriadou1, I Hamzavi2, A G Pandya3, P Grimes4, J E Harris5, R H Huggins2, H W Lim2, N Elbuluk6, B Bhatia2, A Tovar-Garza3, A F Nahhas2, T Braunberger2, K Ezzedine7. 1. Centre of Evidence Based Dermatology, Kings Meadow Campus, University of Nottingham, Nottingham, U.K. 2. Multicultural Dermatology Center, Henry Ford Hospital, Detroit, MI, U.S.A. 3. Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A. 4. Vitiligo and Pigmentation Institute of Southern California, Los Angeles, CA, U.S.A. 5. Department of Dermatology, Vitiligo Clinic and Research Center, University of Massachusetts, Medical School, Worcester, MA, U.S.A. 6. The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, U.S.A. 7. Department of Dermatology, Hospital Henri Mondor, UPEC-Université Paris-Est Créteil, Paris, France.
Abstract
BACKGROUND: There is no cure or firm clinical recommendations for the treatment of vitiligo. One of the main issues is the heterogeneity of outcome measures used in randomized controlled trials for vitiligo. OBJECTIVES: To define successful repigmentation from the patients' point of view and to propose how and when repigmentation should be evaluated in clinical trials in vitiligo. METHODS: We conducted three workshops with patients with vitiligo and their parents or caregivers. Workshop 1 was held at World Vitiligo Day (Detroit, MI), workshop 2 at the University of Texas Southwestern Medical Center and workshop 3 at the Vitiligo and Pigmentation Institute of Southern California, University of California. RESULTS: Seventy-three participants were recruited. Consensus on the following questions was achieved unanimously: (i) the definition of 'successful repigmentation' was 80-100% of repigmentation of a target lesion and (ii) both an objective and a subjective scale to measure repigmentation should be used. CONCLUSIONS: This was the largest patients' outcomes workshop. We followed the guidance from the CSG-COUSIN and the Vitiligo Global Issues Consensus Group. Our recommendations to use percentage of repigmentation quartiles (0-25%, 26-50%, 51-79%, 80-100%) and the Vitiligo Noticeability Scale are based on the best available current evidence. A limitation of the research is that the workshops were conducted only in the U.S.A., due to pre-existing organisational support and the availability of funding.
BACKGROUND: There is no cure or firm clinical recommendations for the treatment of vitiligo. One of the main issues is the heterogeneity of outcome measures used in randomized controlled trials for vitiligo. OBJECTIVES: To define successful repigmentation from the patients' point of view and to propose how and when repigmentation should be evaluated in clinical trials in vitiligo. METHODS: We conducted three workshops with patients with vitiligo and their parents or caregivers. Workshop 1 was held at World Vitiligo Day (Detroit, MI), workshop 2 at the University of Texas Southwestern Medical Center and workshop 3 at the Vitiligo and Pigmentation Institute of Southern California, University of California. RESULTS: Seventy-three participants were recruited. Consensus on the following questions was achieved unanimously: (i) the definition of 'successful repigmentation' was 80-100% of repigmentation of a target lesion and (ii) both an objective and a subjective scale to measure repigmentation should be used. CONCLUSIONS: This was the largest patients' outcomes workshop. We followed the guidance from the CSG-COUSIN and the Vitiligo Global Issues Consensus Group. Our recommendations to use percentage of repigmentation quartiles (0-25%, 26-50%, 51-79%, 80-100%) and the Vitiligo Noticeability Scale are based on the best available current evidence. A limitation of the research is that the workshops were conducted only in the U.S.A., due to pre-existing organisational support and the availability of funding.
Authors: Jonathan M Batchelor; Kim S Thomas; Perways Akram; Jaskiran Azad; Anthony Bewley; Joanne R Chalmers; Seau Tak Cheung; Lelia Duley; Viktoria Eleftheriadou; Robert Ellis; Adam Ferguson; Jonathan Mr Goulding; Rachel H Haines; Hamdi Hamad; John R Ingram; Bisola Laguda; Paul Leighton; Nick Levell; Areti Makrygeorgou; Garry D Meakin; Adam Millington; Malobi Ogboli; Amirtha Rajasekaran; Jane C Ravenscroft; Andrew Rogers; Tracey H Sach; Miriam Santer; Julia Stainforth; Wei Tan; Shyamal Wahie; Jennifer White; Maxine E Whitton; Hywel C Williams; Andrew Wright; Alan A Montgomery Journal: Health Technol Assess Date: 2020-11 Impact factor: 4.014
Authors: Nanja van Geel; Iltefat H Hamzavi; Amit G Pandya; Albert Wolkerstorfer; Julien Seneschal; Amit Garg; Phyllis Spuls; Caroline B Terwee; Sue Mallett; Reinhart Speeckaert; Jean Marie Meurant; Viktoria Eleftheriadou; Khaled Ezzedine Journal: Trials Date: 2022-07-23 Impact factor: 2.728